Navigation Links
Pevion Biotech Appoints New CEO and Secures CHF 10 Million Financing
Date:9/7/2010

Pevion Biotech Appoints New CEO and Secures CHF 10 Million Financing -- BERNE, Switzerland, September 7, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Personnel Announcements Click to view news release full screen  

Pevion Biotech Appoints New CEO and Secures CHF 10 Million Financing

 

BERNE, Switzerland, September 7, 2010 /PRNewswire/ -- Pevion Biotech AG announced today the appointment of Evert Kueppers as its new Chief Executive Officer, succeeding Thomas Stauffer.

"We would like to thank Thomas for his excellent contributions over the years and wish him all the best in his new position," said Klaus Breiner of BB Biotech Ventures and Chairman of the Board of Directors. "We are very pleased that we could attract Evert to become the new CEO of Pevion. With his experience and hands-on approach, Evert is a perfect fit to lead the Company in this exciting phase."

Prior to joining Pevion, Evert Kueppers was CEO of Pieris AG, a Munich-based biotechnology company, which he successfully restructured and refinanced, raising a total US$ 45 million. Before that, Evert was Head of Business Development at IDEA AG, where he was instrumental in corporate development and partnering activities. Before joining the biotech industry, he spent several years in the International Operations of BASF Pharma (now Abbott Labs) and was a management consultant with the global health care team of AT Kearney in London. Evert holds an advanced degree in Biomedical Sciences from Leiden University and an MBA from RSM/Erasmus University. He currently also serves on the Board of Cenix Bioscience.

At the same time, the Company secured further financing commitments of CHF 10 million from its existing investors, BZ Bank, BB Biotech Ventures and Core Capital. Pevion plans to raise additional financing over the next twelve months to broaden and further its pipeline. "Pevion has reached an important stage in its development as its candidate products reach for critical milestones. This financing commitment should take the Company a long way towards achieving further product validation and reaching important company value inflection points," added Joseph Manko of BZ Bank and member of the Board of Directors. "We are looking forward to working with Evert to deliver on Pevion's potential."

"The use of virus-like particles is a proven approach to develop effective and safe vaccines," said Evert Kueppers, CEO of Pevion Biotech. "I am excited to take on this new challenge to bring the company to the next level, working with a team of highly skilled researchers and vaccine developers."

About Pevion Biotech

Pevion Biotech is an independent Swiss vaccine company that develops next generation vaccines based on its clinically and commercially validated virosome technology. Its proprietary pipeline includes a clinical stage candidiasis vaccine and preclinical programmes in RSV and pandemic flu. A clinical stage malaria vaccine candidate has been outlicensed and the Company`s technology is being used for an HIV vaccine currently in human trials. The Company has in-house development capability and expertise, including a state-of-the-art and industrially scalable GMP manufacturing process. Located near Bern, Pevion was founded in 2002 as an industrial spin-off of Bachem AG (SWX: BANB) and Berna Biotech, now Crucell, (SWX: CRX), and raised a total of CHF 45 million to date from its founders and investors, BZ Bank, BB Biotech Venture and Core Capital Partners.

About Virosomes

Virosomes are the only regulatory and market-approved vaccine technology to fulfill carrier and adjuvant functions in one. Essentially, virosomes represent reconstituted empty influenza virus envelopes, devoid of the genetic material of the source virus. As such, virosomes do not replicate and are therefore an ideal combination of carrier plus adjuvant for almost any given antigen, including peptide or protein derived antigens. Two virosome-based vaccines (Epaxal(R) and Inflexal(R) V, marketed by Crucell) are licensed in over 40 countries, and more than 50 million doses of these vaccines have been commercially distributed, thereby providing a solid safety and efficacy track record.

Contact: Evert Kueppers, CEO Phone: +41-31-550-44-44 E-Mail: evert.kueppers@pevion.com
'/>"/>

SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
4. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
7. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
8. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
9. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016 According to responses from ... than one-third (38%) of patients with non-small cell lung cancer ... factor receptor (EGFR) genetic mutation status. The findings of the ... LBA ID #6067 #P3.02b ) at the 2016 World ... . The survey results revealed an overall ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 ... II trial in patients with unresectable malignant pleural ... survival (PFS). The data, presented at the 17 ... in Vienna , showed nintedanib ... to placebo plus pemetrexed/cisplatin, with a significantly improved ...
(Date:12/7/2016)... Today, Stock-Callers.com presents four Biotech equities ... ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ), ProNAi ... (NASDAQ: AVXS ). From its peak in July ... reach a level equal to what it saw at the ... for the year, it has still out-performed other market sectors, ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that heart ... major study analyzing heart attacks among 138,602 people recorded a 35% higher number of ... would all agree of course–no time of year is a good time for a ...
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
Breaking Medicine News(10 mins):